Aceto Corp. plans to begin selling a generic drug to treat overactive bladder, executives said Monday.
The Port Washington-based manufacturer of drugs and chemicals will launch oxybutynin chloride extended-release tablets USP, a generic version of Ditropan XL tablets from drugmaker Janssen Pharmaceuticals Inc.
The tablets are used for overactive bladder. They will be manufactured and sold by Aceto’s Rising Pharmaceuticals Inc. subsidiary in New Jersey.
U.S. sales of existing versions of the drug were $156 million in the 12 months ended Aug. 31, according to the health care research firm IMS Health.